News Briefs: Fresenius’ Conexxence and Bomyntra Launch

Jul 17
Jul 17, 2025

Fresenius Kabi AG’s Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht) have launched in the U.S., the manufacturer said on July 1. The launch of the biosimilars of Amgen Inc.’s Prolia (denosumab) and Xgeva (denosumab) follows that of Sandoz’s first-to-market Jubbonti (denosumab-bbdz) and Wyost (denosumab-bbdz) in June. The FDA approved the receptor activator of nuclear factor-kappa B ligand (RANKL) inhibitors on March 25, 2025. The new agents are approved for all indications of their reference products.
Read more
© 2025 MMIT

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. She also has written for Spotlight on Market Access since its 2017 launch. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at Hem Aware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.